ArticleCancer2008
Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.
Article in Cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Guideline
- Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.Hematology/oncology and stem cell therapy · 2012Guideline
- Chronic kidney disease after hematopoietic cell transplantation: a systematic review.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2008Pooled it
- Trial
- Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor.Haematologica · 2011Trial
- Incidence and risk factors for chronic kidney disease after hematopoietic stem cell transplantation.Renal failure · 2025Article
- Late Effects Following Hematopoietic Stem Cell Transplantation Among Childhood Transplant Survivors with Fanconi AnemiaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Article
- Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.Journal of clinical medicine · 2022Review
- Outcomes of kidney injury including dialysis and kidney transplantation in pediatric oncology and hematopoietic cell transplant patients.Pediatric nephrology (Berlin, Germany) · 2021Article
- Late Kidney Morbidity and Mortality in Hematopoietic Cell Transplant Survivors.Transplantation and cellular therapy · 2021Article
- Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach.Journal of blood medicine · 2020Review
- Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review.Clinical and experimental nephrology · 2019Review
- An Overview of Kidney Disease Following Hematopoietic Cell Transplantation.Internal medicine (Tokyo, Japan) · 2018Review
- Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: Involvement of Chronic Graft-Versus-Host Disease.Kidney international reports · 2018Article
- Late effects of blood and marrow transplantation.Haematologica · 2017Review
- Article
- Survivorship after allogeneic transplantation-management recommendations for the primary care provider.Current hematologic malignancy reports · 2015Review
- Chronic kidney disease after autologous stem cell transplantation: analysis of a single center experience.International urology and nephrology · 2014Article
- [Complications after allogeneic bone marrow and stem cell transplantation].Der Internist · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe authors investigated the risk of delayed chronic kidney disease (CKD) in 1190 adult hematopoietic cell transplantation (HCT) survivors who underwent HCT for hematologic malignancies or aplastic anemia between 1976 and 1997 and survived for at least 1 year.
methodsCKD was defined as a sustained elevation of serum creatinine that indicated a glomerular filtration rate of <60 mL per minute per 1.73 m2 for > or =3 months. The median age at HCT was 35 years (range, 18.1-68.6 years), and the median length of follow-up was 7.1 years after HCT (range, 1-24.3 years).
resultsSixty patients with CKD were identified, resulting in a cumulative incidence of 4.4% at 5 years (autologous HCT, 3.8%; matched-sibling HCT, 4.5%; unrelated donor HCT, 10%; P = .09 compared with autologous HCT). Older age at HCT (relative risk [RR] per 5-year increment, 1.33; 95% confidence interval [CI], 1.2-1.5), exposure to cyclosporine without tacrolimus (RR, 1.90; 95% CI, 1.1-3.4) or with tacrolimus (RR, 4.59; 95% CI, 1.8-11.5), and a primary diagnosis of multiple myeloma (RR, 2.51; 95% CI, 1.1-5.6) were associated with an increased risk of delayed CKD.
conclusionsIn this study, the authors identified a subpopulation of patients who underwent HCT and remained at increased risk for CKD. The current findings set the stage for appropriate long-term follow-up of vulnerable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.